Veritas Capital Completes Combination of Coronis Health and MiraMed Global Services

Veritas Capital | August 08, 2022 | Read time : 04:00 min

Veritas Capital

Veritas Capital a leading technology and government investor with deep healthcare expertise, announced that an affiliate of Veritas completed the combination of two complementary revenue cycle management businesses: Coronis Health and MiraMed Global Services. The combination creates a scaled RCM platform providing end-to-end technology-enabled solutions to a diverse set of healthcare providers across the U.S. The newly combined company benefits from meaningfully increased scale, end-to-end RCM capabilities across multiple specialties, and robust infrastructure with over 8,500 employees globally.

The combined company will be led by Coronis CEO Stephen Grubbs. MiraMed’s founder and CEO Tony Mira will serve as Vice Chairman of the Board of Directors.

Veritas has a proven track record of driving growth for companies within the healthcare technology market. The firm brings a culture of intense customer focus and accelerating growth through investment in R&D and product innovation.

Coronis is a leading provider of end-to-end RCM solutions to U.S. healthcare providers including primary and specialty physician practices, anesthesia groups, laboratories, emergency medical services, behavioral health centers, FQHCs, and hospitals. Since its founding in 2015, Coronis has rapidly become an industry leader with an emphasis on quality, transparency, and customer satisfaction. Coronis’ solutions address the full RCM continuum for a patient’s journey, allowing clients to focus on delivering high quality patient care to communities they serve. Veritas acquired Coronis from 424 Capital and other minority shareholders.

Founded by Tony and Sue Mira in 1979, MiraMed is a leading provider of end-to-end RCM and business process outsourcing services for anesthesia practices and commercial healthcare clients in the U.S. MiraMed delivers medical coding, billing, and receivables management solutions to regional anesthesia-focused physician practices and other commercial healthcare clients, supported by a highly strategic hybrid onshore/offshore delivery model. Veritas acquired MiraMed from the Mira family, who will retain an ownership position in the combined company.

This combination brings together two highly complementary businesses with a shared mission to improve operations for healthcare providers across the U.S. Coronis’ end-to-end RCM solutions paired with MiraMed’s expertise and global infrastructure creates a robust platform for growth in a highly fragmented market. We look forward to leveraging our expertise in healthcare technology to support the combined company and, in partnership with management, deliver innovative technology-based solutions to ensure the continued success of the company’s healthcare provider clients.”

Ramzi Musallam, CEO and Managing Partner of Veritas Capital

“We are thrilled to partner with Veritas Capital through this combination, which will better position us to help our clients focus on providing what’s most important – the absolute best patient care,” said Mr. Grubbs, CEO of Coronis. “MiraMed has a terrific team and value proposition, and we are confident that, with a larger platform and enhanced resources provided by Veritas, the combined company is poised for continued organic and inorganic growth to benefit our clients, employees, and partners."

“Our family built MiraMed to serve the growing needs of our healthcare clients and their patients. By combining with Coronis, we created a new company with the scale, resources, and global infrastructure to provide an expanded set of solutions to our clients,” said Tony Mira, founder and CEO of MiraMed. “Together, we will expand our operational footprint to serve clients across various specialties and make investments in technology to enhance operations for our clients across the healthcare industry. I look forward to working with the talented team at Coronis, as well as Veritas, as we embark on this next chapter.”

“Our investment in Coronis and partnership with Stephen and the entire management team firmly established how our playbook can create value in the healthcare technology sector,” said 424 Capital Managing Partner Walter Beinecke. “We welcome Veritas as the new stewards of Coronis and wish the team continued success.”

Latham & Watkins LLP served as legal counsel to Veritas. Lincoln International LLC and TripleTree LLC served as financial advisors to Veritas. Guggenheim Securities LLC served as lead financial advisor and Whiteman Osterman & Hanna LLP served as legal counsel to Coronis. Gibson, Dunn & Crutcher LLP served as legal counsel to MiraMed.

About Veritas Capital
Veritas is a longstanding technology investor with a focus on companies operating at the intersection of technology and government. The firm invests in companies that provide critical products, software, and services, primarily technology and technology-enabled solutions, to government and commercial customers worldwide. Veritas seeks to create value by strategically transforming the companies in which it invests through organic and inorganic means.

Leveraging technology to make a positive impact across vitally important areas, such as healthcare, education, and national security, is core to Veritas. We are proud stewards of national assets, improving the quality of healthcare while reducing cost, advancing our educational system, and protecting our nation and allies. 

About Coronis Health
Coronis is a leading provider of end-to-end RCM solutions to U.S. healthcare providers including primary and specialty physician practices, laboratories, and hospitals. By using industry-leading technology combined with high-touch relationship building, Coronis Health allows healthcare practitioners to focus on patient care. 

About MiraMed Global Services
MiraMed is a leading provider of end-to-end RCM and Business Process Outsourcing services for anesthesia practices and commercial healthcare clients in the U.S. MiraMed partners with physician practices, hospitals, health networks, and related industry service organizations to provide a broad portfolio of solutions to streamline operations, improve productivity and ensure compliance.


Bowel cancer screening is a type of screening designed to detect and diagnose bowel cancer (also referred to as colon cancer). Diagnosing and treating bowel cancer in its early stages can help to increase a patient’s chances of recovery.


Bowel cancer screening is a type of screening designed to detect and diagnose bowel cancer (also referred to as colon cancer). Diagnosing and treating bowel cancer in its early stages can help to increase a patient’s chances of recovery.

Related News


Smith+Nephew introduces smart glasses into the operating room to enable remote technical support for UK surgeons during procedures

Smith & Nephew | July 11, 2022

Smith+Nephew the global medical technology company, announces a partnership with Rods&Cones to provide smart surgery glasses and digital remote assistance to customers. By providing customers with smart surgery glasses, Smith+Nephew representatives can 'see' through the eyes of the surgeon, instrumentalist nurse, or any healthcare professional using them, enabling continuous remote support before, during, and after surgical interventions. Initially used in the UK to support the NHS and other customers, this solution allows Smith+Nephew to increase its ability to offer technical support for safe and effective use of its products at the right time from anywhere in the world. The increased complexity of surgery, advancement of technologies, and need for productivity and efficiency is enabled by ensuring a specialist is available remotely to give best possible expertise exactly when they need it, in the least disruptive way. "I am delighted that we have agreed to partner with one of the most innovative companies in the area of remote surgical support," said Simon Tarry, Managing Director of Smith+Nephew's UKI/Nordics region. "This new partnership will enable our team to deliver the highest possible expertise exactly when our customers and patients need it. At the same time, I believe enhancing our ability to support our customers remotely serves patient safety and sustainability to great effect." The multi-year agreement with Rods&Cones allows Smith+Nephew to scale its remote support capability for customers, enabling connectivity with specialist surgeons during minimally invasive surgery. The MIS Kit connects seamlessly to a secure Rods&Cones Remote Expert interface, which allows the user to follow and attend a surgery just as if standing in the OR, but with the exact view of the surgeon or other healthcare professional. "We are thrilled to work with such a great company as Smith+Nephew. The achievements they have made in the MedTech industry, especially within the sphere of repair, regeneration and replacement of soft and hard tissue has been awe-inspiring. This partnership between Smith+Nephew and Rods&Cones will be a great step forward and together we will change healthcare for the better." Bruno Dheedene, CEO and Founding Partner of Rods&Cones About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100. The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. About Rods&Cones Rods&Cones' purpose is to be a catalyst of change in healthcare to improve people's lives. The company provides a remote assistance service used to connect medical experts worldwide. With their state-of-the-art technological devices and a digital remote assistance platform, users can connect safely with surgeons, product specialists, or other medical professionals anywhere in the world, in real-time. Rods&Cones was founded in 2017 by two brothers, Bruno and Jan Dheedene. Based in Amsterdam, The Netherlands, the company has now become a leading international supplier of remote surgical assistance services.

Read More


Nanomix Enters into Distribution Agreement for the eLab System and Future New Products with BIOASIA PTE LTD in Singapore

Nanomix Corporation and BIOASIA PTE LTD. | August 24, 2022

Nanomix Corporation a leader in the development of mobile, affordable, point-of-care diagnostics, announced that it has entered into a distribution agreement with BIOASIA PTE LTD a medical diagnostics distributor located in Singapore. Bioasia will market and distribute the Nanōmix eLab® system in Singapore and Brunei, including the Nanōmix S1 Panel assay and future new test products for the eLab system. “We are pleased to introduce and give access to much needed, new diagnostics to our hospitals and customers. Sepsis and critical infections are a challenge in Singapore in the same way they are around the world. Our partnership with Nanomix will help us bring a unique option to our customers and the healthcare system in Singapore.” Henry Lim, Managing Director of Bioasia Thomas Schlumpberger, Chief Executive Officer of Nanomix, stated, “Nanomix is at the cusp of commercialization and continues to show early successes in executing upon our commercialization strategy. We are excited to see increased interest in our products especially in Asia, beginning in Singapore, which represents a significant and untapped growth opportunity for Nanomix.” John Hardesky, Chief Commercial Officer of Nanomix, stated, “Singapore has been ranked as one of the most efficient healthcare systems in the world for many years. The Nanōmix eLab® analyzer runs the S1 Panel assay rapidly, diagnosing critical infections including sepsis in 12 minutes which will undoubtedly lead to breakthroughs in earlier sepsis patient diagnosis.” Sepsis is a recognized global health crisis. Early identification and treatment are a need and a challenge for healthcare professionals around the globe. For many reasons, sepsis can be difficult to identify and is frequently under-diagnosed in the earliest stages. It affects as many as 50 million people every year, leading to approximately 11 million deaths annually. The Nanōmix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanōmix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab® Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration. About BIOASIA PTE LTD Bioasia was established in 2005 focusing on medical marketing and distribution of critical care products and monitoring equipment for patients requiring intensive care in intensive care settings. Our staff are professional biomedical engineers with knowledge of ISO13485. We work with medical professionals in hospital settings to ensure in-hospital equipment are at optimal working conditions for effective patient monitoring and results. Bioasia has represented various medical device companies in Singapore and Brunei markets since 2005. Bioasia is GDPMDS certified. About Nanomix Corporation Nanomix is developing mobile point-of-care diagnostics with its Nanōmix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.

Read More


Avail Reaches Significant Network Expansion Milestone with the Signing of its 50th MedTech Contract

Avail Medsystems | August 05, 2022

Avail, the digital hub of the operating room enabling the medical technology and healthcare industries to work smarter to advance patient care, announced the addition of a 50th MedTech organization to its telepresence network. With the signing of this contract, the Avail platform is poised to enable hundreds of thousands of people to collaborate, educate, and share surgical and MedTech expertise between operating rooms and remote locations in real time. "The Avail platform was built to connect the MedTech industry more frequently, efficiently and seamlessly to surgeons and interventionalists, enabling them to work together more closely to advance medicine. With this exciting milestone, the digital evolution of MedTech is well underway. Many of our MedTech partners are integrating Avail into their daily processes to expand the productivity and reach of their commercial teams, thus helping representatives to better engage with customers and support their success." Daniel Hawkins, CEO of Avail For some of the world's largest and most respected MedTech companies specializing in devices for neurosurgery, interventional cardiology, interventional radiology, vascular surgery, and orthopedic surgery, among others — Avail has positively changed business practices in myriad ways. These include enabling faster product training and expanded reach for field teams, dramatically increasing the time they have available to sell products and support live procedures. In addition, MedTech companies and surgeons have realized the mutual benefits of using Avail to collaborate during unplanned cases when field representatives are unable to reach remote locations to join in person. With skyrocketing travel costs and staff shortages, Avail's approach to collaboration has allowed physician education and product launch programs not only to continue, but to operate more efficiently and rapidly. Other uses include enabling the acceleration of product innovation by allowing engineering and R&D teams to better connect with providers. "As far as technology goes, the Avail experience has completely raised the bar for our Professional Education Programs — Avail makes us look good," stated John Vogrin, Senior Manager, Surgical Care Services for Cochlear Americas. "But more importantly, using Avail has allowed Cochlear to reduce travel for members of our sales team and give them back countless hours of their personal lives while improving the training experience and shortening the time it takes to complete. It's a win-win-win-win for our company, employees, customers, and their patients." Avail's footprint of consistent, purpose-built hardware in procedure rooms, along with integrated software created for that hardware, serves as the foundation of the company's surgical telepresence platform. The mobile Avail console includes edge-based computing and a large display monitor and is connected securely to the cloud to stream high-quality audio, video, and surgical imaging to remote participants in a HIPAA-HITECH protected environment. "Future-forward MedTech companies and healthcare systems not only need better, faster means of collaboration, but they want a way to share their own software capabilities to and from the OR," stated James Domine, CTO of Avail. "Avail's consistent hardware footprint provides eyes and ears into the operating room and will also enable the sharing of applicable third-party software capabilities, including AI and machine learning, which can be displayed on the large Avail console monitor to further elevate the collaborative experience. This can help improve processes and speed the adoption of new products that better meet the changing healthcare environment." News of the 50th MedTech contract follows Avail's recent announcements of another company expansion and a partnership with the Stroke Thrombectomy and Aneurysm Registry (STAR), which enables participating neurosurgeons to collaborate and share expertise, regardless of their locations. About Avail Medsystems Avail enables the MedTech industry and healthcare providers to work together more often and more efficiently, harnessing expertise and technology in and out of the OR to accelerate the innovation, adoption, and reach of tools and techniques to improve patient care. Avail does this by placing a consistent, mobile, hardware platform with integrated software into operating rooms, audibly and visually connecting remote participants and serving as the hub for advanced digital capabilities including AI and machine learning, in a secure cloud-based digital telepresence network. Today, 50 MedTech organizations have contracted with Avail to rethink commercial models, reduce inefficiencies, and enhance the reach and timeliness of collaboration. Avail was founded in 2017 by MedTech veterans with a vision to leverage Silicon Valley technology expertise to evolve the industry and enable MedTech and healthcare to deliver the best care possible. Avail.io

Read More